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1. Introduction
Aortic stenosis (AS) is the most frequent type of valvular heart disease in Europe and North
America. It mainly presents as calcified aortic stenosis in older adults (2-7% of the popula‐
tion> 65 years), which is the most common cause of valve replacement in the western world.
Its incidence increases with age [1]. With the increasing age and life expectancy of the popu‐
lation, an increase in the prevalence of aortic stenosis had been observed. Furthermore, the
elderly patient usually presents multiple comorbidities associated with increased surgical
risk. Aortic valve replacement (AVR) is currently the treatment of choice in patients with
symptomatic aortic stenosis and/or left ventricular systolic dysfunction (see Indications for
surgery), even though some cases present high or extremely high surgical risk.
Our goal is to update the treatment of severe aortic stenosis in high-risk patients, mainly the
elderly and those cases where risk assessment scales indicate a high- or very high-risk pa‐
tient. Here we analyse the role of new therapeutic approaches in the treatment of these pa‐
tients and their short and long-term results, as well as the use of new devices and prosthesis.
2. Etiology
AS without accompanying mitral valve disease is more common in men than in women [2]
and rheumatic etiology is currently rare. Age-related degenerative calcific AS is currently
the most common cause of AS in adults and the most frequent reason for aortic valve re‐
placement (AVR) in patients with AS. Sclerosis of the aortic valve is observed in up to 30%
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of elderly people: 25% of people aged 65 to 74, and 48% of people older than 84 years [3,4].
This calcific disease progresses from the base of the cusps to the leaflets, eventually causing
a reduction in leaflet motion and effective valve area without commissural fusion. Calcific
AS is an active disease process characterized by lipid accumulation, inflammation, and calci‐
fication, with many similarities to atherosclerosis. In approximately half of cases there is a
bicuspid aortic valve basis. Bicuspid aortic valve valvulopathy affects 2% of the population,
making it the most frequent congenital anomaly, representing the more common cause
among young adults [5].
3. Evaluation and grading the degree of stenosis
Patient history and physical examination remain essential. Careful exploration for the pres‐
ence of symptoms (shortness of breath on exertion, angina, dizziness, or syncope) is critical
for proper patient management. It is important to be aware that patients may not notice
symptoms but they significantly reduce their activities. The characteristic systolic murmur
draws attention and guides further diagnostic work in the right direction. However, on oc‐
casion the murmur may, be faint and the primary presentation may be heart failure of un‐
known cause. The disappearance of the second aortic sound is specific to severe AS,
however, it is not a sensitive sign.
Several studies [6-9] reports that biomarkers such as B-type natriuretic peptide (BNP) has
been shown to be related to functional class and prognosis, particularly in AS and MR. In
fact, Lancellotti et al. [9] reports in their study that a left atrial area index of > or = 12.4
cm2/m2, systolic annular velocity of < or = 4.5 cm/s, E/Ea ratio >13.8, late diastolic annular
velocity of < or = 9 cm/s, and BNP of > or = 61 pg/ml were identified as the best cutoff values
to predict events (death, symptoms, or surgery). They found, in asymptomatic AS, tissue
Doppler imaging and BNP measurements provide prognostic information beyond that from
clinical and conventional echocardiographic parameters. However, Natriuretic peptides
have been shown to predict symptom free survival and outcome in normal- and low-flow
severe AS and may be useful in asymptomatic patients, helping to discriminates those pa‐
tients who can benefits from an early intervention [7-9]. Nevertheless, evidence regarding its
incremental value in risk stratification remains limited so far.
Echocardiography is indicated when there is a systolic murmur of grade III/VI or higher, a
single S2, or symptoms that might be due to AS [10]. A 2-dimensional (2D) echocardiogram
is valuable for assessing valve anatomy and function and determining the LV response to
pressure overload. In nearly all patients, the severity of the stenotic lesion can be defined
with Doppler echocardiographic measurements. Echocardiography is also used to assess LV
size and function, degree of hypertrophy, and presence of other associated valvular disease.
Transoesophageal echocardiography (TOE) is rarely helpful for the quantification of AS, as
valve area planimetry becomes difficult in calcified valves [11] however, it is useful when
transthoracic visualization is poor and leaflets only moderately calcified [12]. TOE may,
however, provide additional evaluation of mitral valve abnormalities and has gained impor‐
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tance in assessing annulus diameter before TAVI and in guiding the procedure. Intraproce‐
dural TOE enables us to monitor the results of percutaneous procedures [11]. Three-
dimensional TOE offers a more detailed examination of valve anatomy than two-
dimensional echocardiography and is useful for the assessment of complex valve problems
or for monitoring surgery and percutaneous intervention [11]. Three-dimensional echocar‐
diography (3DE) is useful for assessing anatomical features which may have an impact on
the type of intervention chosen, if it is needed. AS severity could be graded on the basis of a
variety of hemodynamic and natural history data, using definitions of aortic jet velocity,
mean pressure gradient, valve area and velocity ratio as shown in Table 1.
Aortic Stenosis
Indicator Mild Moderate Severe
Aortic jet velocity (m/s) 2.6-3 3-4 ≥4
Mean gradient (mmHg) ≤30(25) 30-50(25-40) ≥50(40)
Indexed AVA (cm2/m2) ≥0.9 0.6-0.9 ≤0.6
AVA (cm2) ≥1.5 1-1.5 ≤1
Velocity ratio ≥0.50 0.25-0.50 ≤0.25
Table 1. Classification of the Severity of Aortic Valve Disease in Adults
Based on the European Society of Cardiology (ESC) Guidelines on the management of valv‐
ular heart disease [12], American College of Cardiology/American Heart Association (ACC/
AHA) Guidelines for the Management of Patients With valvular heart disease [10] and
ASE/EAE Recommendations for Quantitation of Stenosis Severity, [13] ACC/AHA guide‐
lines use lower mean gradient cutoffs as indicated in parentheses. The ESC definitions apply
only in the presence of normal flow conditions. The velocity ratio is included in the
ASE/EAE guidelines only.
Multi-slice computed tomography (MSCT) and cardiac magnetic resonance (CMR) provide
additional information on the assessment of the ascending aorta when it is enlarged. MSCT
may be useful in quantifying the valve area and coronary calcification, which aids in assess‐
ing prognosis. MSCT may contribute to the evaluation of the severity of valve disease, par‐
ticularly in AS, either indirectly by quantifying valvular calcification, or directly through the
measurement of valve planimetry. Also, MSCT has become an important diagnostic tool for
evaluation of the aortic root, the distribution of calcium, the number of leaflets, the ascend‐
ing aorta, and peripheral artery pathology and dimensions before undertaking TAVI [11]. In
patients with inadequate echocardiographic quality or discrepant results, CMR should be
used to assess the severity of valvular lesions—particularly regurgitant lesions—and to as‐
sess ventricular volumes and systolic function, as CMR assesses these parameters with high‐
er reproducibility than echocardiography [11]. In practice, the routine use of CMR is limited
because of its limited availability, compared with echocardiography. Due to its high nega‐
tive predictive value, MSCT may be useful in excluding CAD in patients who are at low risk
New Therapeutic Approaches to Conventional Surgery for Aortic Stenosis in High-Risk Patients
http://dx.doi.org/10.5772/54333
453
of atherosclerosis [11]. MSCT plays an important role in the work-up of high-risk patients
with AS considered for TAVI. The risk of radiation exposure—and of renal failure due to
contrast injection—should, however, be taken into consideration.
There are contraindications for exercise testing in symptomatic patients with AS, however it
is useful for unmasking symptoms and in the risk stratification of asymptomatic patients
with severe AS [12]. Stress tests are currently under-used in patients with asymptomatic AS.
In some patients, it may be necessary to proceed with cardiac catheterisation and coronary
angiography at the time of initial evaluation [10]. This could be appropriate if there is a dis‐
crepancy between clinical and echocardiographic examinations or if symptoms might be
due to coronary artery disease (CAD).
4. Indications for surgery
Early valve replacement should be strongly recommended in all symptomatic patients with
severe AS, because it is the only effective treatment. Thus, the development of symptoms
identifies a critical point in the natural history of AS. The interval from the onset of symp‐
toms to the time of death is approximately 2 years in patients with heart failure, 3 years in
those with syncope, and 5 years in those with angina, with a high risk of sudden death
(Figure 1).
Figure 1. Natural History. Ross J Jr. & Braunwald E, 1968 [14]
There is some disagreement about the optimal timing of surgery in asymptomatic patients,
and the decision to operate on this kind of patient requires careful weighing of the benefits
against the risks. Early elective surgery, at the asymptomatic stage, can only be recommend‐
ed in selected patients, with low operative risk [12]. A proposed management strategy for
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patients with severe AS based on the ESC Guidelines on the management of valvular heart
disease [12] and ACC/ AHA Guidelines for the Management of Patients with valvular heart
disease [10] is shown in Figure 2.
Although there are no prospective randomized trials, data from retrospective analysis indi‐
cates that patients with moderate AS (mean gradient in the presence of normal flow 30–50
mmHg, valve area 1.0–1.5 cm2) will generally benefit from valve replacement at the time of
coronary surgery. However, individual judgement must be recommended [12], based on the
evolution of the echocardiography severity parameters and the patient's clinical evaluation.
Figure 2. Management of Severe Aortic Stenosis.
Based on the ESC Guidelines on the management of valvular heart disease [12] and ACC/
AHA Guidelines for the Management of Patients with valvular heart diseaseb [10].
ACC/AHA recommendations has been shown in parentheses.
5. Risk stratification
Patient selection for AVR for AS is well outlined by ACCF/AHA and ESC guidelines. Prob‐
lems arise when the patients present significant symptoms and significant structural disease,
complicated by the presence of significant comorbidity. A number of risk algorithms for car‐
diac surgery have been developed. Experience accrued since the development of the Parson‐
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net scale reveals that this scale assigns too much weight to age. Nowadays the STS score and
logistic EuroSCORE are the most commonly used. These provide information concerning
short term operative risks, however, they are not able to predict symptom resolution, quali‐
ty-of-life improvement, or return to independent living.
As discussed above (see also Evaluation and Grading the Degree of Stenosis), several stud‐
ies have reported the usefulness of BNP in risk stratification of asymptomatic or mildly
symptomatic patients, which could help to discriminate which patients would benefit from
an early surgical management. However, there is not enough evidence to recommend the
routine use of these biomarkers.
Although both are accurate in low-risk patients, accuracy is reduced in higher-risk subsets
[15]. The logistic EuroSCORE is based on 12 covariates derived from 14,799 patients under‐
going all types of cardiac operations in 8 European countries in 1995. On the other hand, the
STS risk predictor is based on 24 covariates derived from 67,292 patients undergoing isolat‐
ed AVR only in the United States between 2002 and 2006. Both use an algorithm based on
the presence of coexisting illnesses in order to estimate 30-day operative mortality. There is
a much simpler variation of the EuroSCORE logistic model, which can be calculated at the
patient's bedside, adding points manually. This model is called the additive EuroSCORE. It
assigns a specific value to each risk factor, and the points are simply added to obtain the es‐
timated operative mortality rate.
With improved outcomes after cardiac surgery in more recent years, EuroSCORE has be‐
come less well calibrated. EuroSCORE II has been developed using data from 22.381 pa‐
tients who underwent cardiac surgery during 2010, and represents a necessary and timely
update of the original EuroSCORE models. EuroSCORE II improves on the original logistic
EuroSCORE, though mainly for combined AVR and CABG cases. However, concerns still
exist, about its use for isolated AVR procedures, aortic surgery and miscellaneous proce‐
dures. There is still room for improvement in risk modelling and several studies are current‐
ly being carried out to validate EuroScore II. Nevertheless, Grant et al [16] report that
EuroSCORE II performs well overall in contemporary UK adult cardiac surgery, with good
discrimination for all kinds of cardiac surgery; in fact, they report that the logistic Euro‐
SCORE is now obsolete and their study demonstrates that it is appropriate to use Euro‐
SCORE II as a generic risk model for contemporary UK cardiac surgery.
There is growing debate about the definition of high-risk patients and the validity of risk as‐
sessment using different risk-scoring systems for prediction of mortality (see also High-
Risk Patient). Current models do not include some risk factors that may be particularly
important in the prediction of outcomes for high- or very high-risk populations including
frailty, pulmonary hypertension (PH), porcelain aorta, and the presence of hepatic dysfunc‐
tion, although all these have been included in EuroSCORE II.
Nevertheless, the sample of elderly patients considered for the design of these scales repre‐
sents a small proportion of the population, resulting in less accurate risk assessment, and in‐
terpretation should be made with caution. In this regard, a recent study which included
1245 elderly patients (mean age 77.2 years) who underwent AVR with or without CABG re‐
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ports that only STS-PROM correlated with mortality rates [17]. Thielmann et al [18] also re‐
port that the logistic EuroSCORE and the Parsonnet score clearly overestimated the risk of
mortality, whereas the STS score and the additive EuroSCORE were much more accurate in
predicting the risk of mortality.
Certain authors, such as Rosenhek [19] and others, suggest the need to include other varia‐
bles such as cognitive function and functional capacity in surgical risk stratification, mainly
in the elderly group. There are physiological characteristics inherent to elderly patients that
make them different in risk estimation; an example of this is the amount of creatinine con‐
sidered in the EuroSCORE scale as a predictor of mortality. This scale assigned a particular
score (2 points) to patients with creatinine levels greater than 2.26 mg / dl, which through a
logistic regression analysis could estimate risk in percentage terms. However creatinine is
not the best parameter to define renal function and its value can be influenced by various
factors such as age, race, muscle mass and metabolic state, as has been demonstrated in sev‐
eral studies, hence glomerular filtration rate provides a much more accurate estimation [20].
Obviously in the elderly there is a physiological involution of organs and systems that
should be taken into account since surgery represents a stressful situation that can reveal or
tip the balance for certain pathologies. However, numerous reports have demonstrated ex‐
cellent results in terms of morbidity and mortality in most patients. Hospital mortality is sig‐
nificantly related to the preoperative presence of depressed left ventricular systolic function,
pulmonary hypertension, symptoms of heart failure, kidney failure, long-standing mitral
valve disease, and nutritional deficiencies. When these risk factors are absent in the preoper‐
ative period, mortality is similar to that of the youngest patients. It should be emphasized
that risk models serve as one aspect of patient selection, but need to be considered alongside
clinical judgement and other methods of risk assessment.
6. High risk and elderly patients, are they the same?
6.1. Elderly patient
The ageing of the population is an important social and sanitary phenomenon. Consensus
about allowing access to health care unconstrained by age limits, together with increased life
expectancy and advances in highly specialised medicine have brought us to the point where
surgical treatment is indicated in progressively older sectors of the population [21]. The di‐
agnosis and management of valvular heart disease in the elderly has been affected by the
dramatic increase in life expectancy that began in the last half of the 20th century. In the
United States, for example, the number of persons aged 80 years or older is expected to in‐
crease from 6.9 million in 1990 to approximately 25 million by the year 2050. As a result, de‐
generative valve disease is likely to become an increasing problem. In the Helsinki Ageing
Study [22], 501 randomly selected men and women aged 75 to 86 underwent imaging and
Doppler echocardiography. The prevalence of at least moderate aortic stenosis, defined as
an aortic valve area (AVA) ≤1.2 cm2 and velocity ratio ≤0.35, was 5 percent; the prevalence of
critical aortic stenosis (AVA ≤0.8 cm2, and velocity ratio ≤0.35) increased with age from 1 to 2
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percent in persons aged 75 to 76 up to almost 6 percent in those aged 86. With the rapidly
increasing geriatric population, it is common in current practice to have elderly patients re‐
ferred for surgical treatment of AS. In 2006, in the United States, approximately 40% of pa‐
tients undergoing AVR were at least 75 years old Nevertheless, even though valve
replacement is the procedure of choice in this population, currently a large percentage of
suitable candidates are, unfortunately, not referred for surgery, mostly because of their age.
As in [21], increased risk in these patients is related to:
• Ageing, which causes structural changes in the heart and reduces the physiological re‐
serves of most organs, thus impairing the capacity to recover from surgical aggression;
• An increase in associated diseases, as studied by Rodríguez et al [23], especially diabetes,
kidney failure, arterial hypertension, chronic obstructive pulmonary disease, and cerebro‐
vascular disease;
• The advanced phase of heart disease, as indicated by the greater incidence of heart fail‐
ure, depressed left ventricular function, and preoperative pulmonary hypertension;
• Reduction of the inflammatory response to surgical aggression,
• Undernourishment, measured by anthropometric and biochemical parameters, which is a
frequent preoperative finding before cardiac surgery; its incidence is even greater in older
persons and is associated with an increment in postoperative complications due to an im‐
paired response to surgical aggression.
• The increased complexity of surgical techniques for these patients, due to the presence of
severe calcification of the aortic ring and the greater incidence of associated coronary and
valvular surgery, which require longer aortic clamping times.
Age has been considered an independent predictive factor for mortality, but the way to esti‐
mate its influence on the calculation of the risk of surgery has evolved since the introduction
of the Parsonnet risk scale, which gave excessive weight to age. Currently the most accepted
risk assessment tools are the STS-PROM score and EuroSCORE (with the EuroSCORE II cur‐
rently being validated).Although they are widely used, there is a possibility of overestimat‐
ing the operative mortality rates by using these risk-prediction models, and an inescapable
discrepancy between the estimated and observed mortality rate has been acknowledged. In
a study published in Ann Thorac Surg in 2009 Thielmann et al [18] report that the logistic
EuroSCORE clearly overestimates the risk of mortality, whereas the STS score seems to be
more accurate in predicting the risk of mortality. Moat et al. [24] also report the relative lack
of utility of EuroSCORE in risk/outcome prediction for their group of patients and confirm
the need for more sophisticated and procedure-specific (rather than generic) scoring sys‐
tems. There is no perfect method for weighing all of the relevant factors and identifying spe‐
cifically high- and low-risk elderly patients, but this risk can be estimated well in individual
patients, and the decision to proceed with surgery should depend on many factors, includ‐
ing the patient’s wishes and expectations.
Although the proportion of elderly patients with multiple comorbidities is increasing, oper‐
ative outcomes following AVR have improved over the past decade. Likosky et al [25] pub‐
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lished the outcomes of the very elderly undergoing aortic valve surgery in a study
comprising 7584 patients, including 815 over the age of 80. They found that short- and long-
term survival was favourable across all age groups. Specifically, more than half of the pa‐
tients undergoing aortic valve procedures were alive 6 years after surgery. Among patients
under 80 years of age, survival favoured those undergoing isolated AVR procedures, but
among octogenarians, concomitant CABG surgery did not result in reduced survival. Ya‐
mane K et al [26] published the outcome of a single-centre study of conventional AVR in pa‐
tients aged 70 or older. In their analysis, patients aged 80–92 who underwent isolated AVR
or AVR with CABG showed an acceptable mortality rate of 4.0%, comparable to the 3.8%
mortality rate in patients aged 70–79. Brown et al [27] published the outcomes of isolated
AVR in North America by analysing the STS National Database, comprising 108,687 pa‐
tients, and compared the mortality rates in 1997 with those in 2006. In their analysis, patients
aged 70–75 had a mortality rate of 3.2% in 1997 and 2.9% in 2006; for patients aged 80–85,
the mortality rate was 6.3% in 1997 and 4.9% in 2006. These improvements in operative out‐
come over the past decade could be related to multiple factors, including patient selection
and perioperative management. A better understanding of the role of preoperative respira‐
tory preparation, improved myocardial protection of otherwise severely hypertrophic myo‐
cardium, as well as normothermic cardiopulmonary bypass may have contributed to the
improved early postoperative results in recent studies as compared to those several decades
ago. Yamane K et al [26] propose that with the elderly, especially those aged 80 years or old‐
er, goal-oriented strategies such as early extubation, judicious sedation management, medi‐
cation dosage based on renal or liver function, early involvement of physical or occupational
therapists, and speech/swallow specialists are all indispensable.
From a patient’s perspective, functionality after surgery may be more important than simple
survival. Using the Seattle Angina Questionnaire, Huber et al [28] interviewed 136 patients
who were 80 years of age at the time of cardiac surgery (isolated CABG, AVR, or AVR
+CABG). They found that 95% lived in their own homes, and 93% reported that they had
experienced no reduction in their quality of life. Kolh et al [29] interviewed 61 long-term
survivors of AVR and found that 92% of patients believed that having heart surgery at age
80 was a “good choice,” with 88% of patients feeling “as good or better” than they had be‐
fore surgery. Also, Maillet et al [30] reported results from 84 octogenarians undergoing ei‐
ther AVR or AVR+CABG between 1998 and 2001. The majority (91.1%) lived in their own
homes (compared with 75% of the general French population aged 80 years), whereas 26.7%
of patients required help with activities of daily living (compared with 35% to 40% of the
general population). Sundt et al [31] reported functional status and survivorship up to 5
years among 133 patients undergoing AVR with or without CABG. Patient-reported func‐
tional status was comparable to the general population.
Because there is no effective medical therapy and balloon valvotomy is not an acceptable al‐
ternative to surgery, AVR is the gold standard for the treatment of severe stenosis and must
be considered in all elderly patients who have symptoms caused by AS [10]. Age, per se,
should not be considered a contraindication for surgery. Decisions should be made on an
individual basis, taking into account patients’ wishes and cardiac and non-cardiac factors
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[12]. In this population, the need for an emergency operation, or, at the other end of the clin‐
ical spectrum, very early intervention at an asymptomatic stage, should be avoided.
The surgical community worked vigorously over the past two decades to reduce the trauma
of the conventional aortic valve operation. Ongoing studies of transcatheter aortic valve im‐
plantation (TAVI) have demonstrated feasible short- and mid-term results in patients who
were not considered suitable candidates for conventional AVR. Minimally invasive ap‐
proaches like partial upper sternotomy have replaced the conventional complete median
sternotomy when performing AVR in many centres. By aiming for smaller incisions, with‐
out compromising the quality of the operation and the effectiveness of myocardial protec‐
tion, improved early outcomes have been achieved.
In a prospective randomised trial, Dogan et al [32] show that minimally invasive AVR can
be performed with only slightly longer operative times, good cosmetic results and improved
rib cage stability as well as significantly less blood loss. Furthermore, limited surgical access
had no negative effects on the patients' neurological outcome nor the efficacy of myocardial
protection. More recently, the implantation technique for AVR has also been modified, with‐
out compromising the hemodynamic performance of the valve substitute, all in order to re‐
duce implantation times, and therefore reduce ischemia in the myocardium and
cardiopulmonary bypass times. In 2009 Martens et al [33] reported on initial clinical experi‐
ences with the sutureless, nitinol-stented Enable (Medtronic Inc., Minnesota, USA) aortic
valve prosthesis in 32 patients. Implantation time could be significantly reduced, down to
9±5 minutes, the first report of multi-centre experience with this particular valve substitute
and implantation technique in 140 patients was published in the European Journal of Cardi‐
othoracic Surgery in 2011. Reproducibility as well as feasibility and safety were demonstrat‐
ed with the ATS 3f Enable® Bioprosthesis. Valve implantation resulted in excellent
hemodynamics and significant clinical improvement. Further comparative studies are under
way to prove the clinical benefit using this less-time-consuming implantation technique ver‐
sus the conventional one.
6.2. High risk patient
How could we define a cardiac high-risk patient? Which parameters must we consider in
order to assess risk? Which is the most accurate assessment tool to calculate a patient's risk?
We could define high risk cardiac patients as those who present several factors that signifi‐
cantly affect their outcome after surgery and could compromise their survival. Multiple ser‐
ies have documented that patients were deemed to have a high risk of operative
complications or death on the basis of coexisting conditions such as advanced age, diabetes
mellitus, existence of preoperative shock, LVEF ≤40%(≤30%), preoperative NYHA class III or
IV, concomitant CAD, concomitant surgical procedure (CABG, valve surgery or surgery on
thoracic aorta), renal failure and chronic obstructive pulmonary disease (COPD). Although
attempts have been made to identify the high-risk population for AVR, there is currently no
ideal model for precisely identifying high-risk patients. STS-PROM score and the European
System for Cardiac Operative Risk Evaluation (EuroSCORE) have been used as part of the
inclusion/exclusion criteria for the TAVI trials and to quantify the operative risk of conven‐
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tional AVR. Nevertheless, several previous reports on TAVI defined high-risk patients as
patients with a logistic EuroSCORE between 10% and 30% [18]. Smith et al [34] in a TAVI
versus AVR paper published in the New England Journal of Medicine in 2011 used as a
guideline a score of at least 10% on the risk model developed by the STS to define high-risk
patients. However, there are multiple additional risk factors, which are not currently consid‐
ered by existing risk scoring systems; for example the presence of a porcelain aorta and con‐
siderations such as social integration, mobility, frailty, and the individual's overall health
status must be taken into account, as well as the patient’s wishes and expectations. A further
definition that must be taken into account for evaluation of those patients who underwent
TAVI is that very or extremely high-risk patients are those with a logistic EuroSCORE above
30% or STS score higher than 15% (see Table 2). The 2012 ACCF/AATS/SCAI/STS Expert
Consensus Document on Transcatheter Aortic Valve Replacement [15] used the term prohibi‐
tive risk. This includes some patients for whom surgery might be deemed unsuitable based
on the physician’s assessment of the patient’s risk for surgery; whereas in others, the sur‐
geon may decide that the operation cannot be performed successfully because of technical
considerations.
Risk assessment tool
EuroSCORE STS score
High risk 10-30% "/>10%
Very or extremely high risk "/>30% "/>15%
Based on the 2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement
[15].
Table 2. Risk Assessment
In the absence of evidence in the literature and recommended guidelines, the determination
of inoperability in any given patient depends on the judgement of the Heart team. It is gen‐
erally agreed that patients with limited life expectancy due to concurrent conditions such as
malignant tumours, dementia, primary liver disease or COPD, among others, are not appro‐
priate for AVR. Frailty and poor physical condition are known to result in an inability to re‐
cover from major heart surgery such as AVR. These conditions can potentially contribute to
increased surgical mortality and morbidity in the elderly. The surgeon may judge a patient
inoperable as a result of technical considerations that preclude safe performance of AVR,
such as prior mediastinal irradiation, porcelain aorta or severe periannular calcification, se‐
vere atheromatous disease, prior cardiac operations, and other conditions such as the inter‐
nal mammary artery crossing the midline. In summary, a substantial percentage of patients
with AS are judged to be inoperable for surgery based primarily on the physician’s or sur‐
geon’s determination of operative risk and probability of survival [15]. Although some pa‐
tients may be found to be inoperable for technical and surgical reasons, most inoperable
patients are considered to be too ill due to associated comorbid conditions. In conclusion,
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the decision to proceed with AVR or TAVI requires careful weighing of the potential for im‐
proved symptoms and survival and the morbidity and mortality of surgery.
7. Surgical approach
7.1. Conventional AVR
Aortic valve replacement has permitted thousands of lives to be saved since it was first suc‐
cessfully carried out by Harken and Starr in 1960 [35, 36]. Since then, advances in prosthetic
technology including improved hemodynamics, durability and thromboresistance, and tech‐
niques in cardiac surgery such as cardioplegia, management of the small aortic root, and re‐
placement of associated aortic aneurysm have resulted in improvements in both operative
and long-term results.
The conventional approach to AVR is the following: A mid-line incision and sternotomy is
made and a pericardial well created. The patient is cannulated via the aorta and a single at‐
rial venous cannula. After cross-clamping of the aorta, a transverse aortotomy is made ap‐
proximately 1 cm above the take-off of the right coronary artery, slightly above the level of
the sinotubular ridge (Figure. 3).
Figure 3. Transverse aortotomy
The incision is extended three-quarters of the way around the aorta, leaving the posterior
one-quarter of the aorta intact allowing excellent visualization of the native aortic valve and
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annulus. The leaflets of the aortic valve are excised to the level of the annulus and the annu‐
lus is thoroughly debrided of any calcium. Braided 2-0 sutures with pledgets are applied.
Beginning at the non-coronary commissure, the annulus is encircled with interrupted mat‐
tress sutures (Figure 4) extending from the ventricular to the aortic surface.
Figure 4. Aortic annulus encircled with interrupted mattress sutures
Next, each half of the suture bundles are implanted in the sewing ring and the prosthesis
seated. The sutures are tied first at the left coronary cusp extending to the mid-portion of the
right coronary cusp. Lastly, the sutures of the non-coronary cusp are secured, seating the
valve appropriately. In case of mechanical valve prosthesis leaflet motion should always be
checked and the surgeon must be assured that the coronary arteries are not obstructed. The
aortotomy is closed with a double layer of polypropylene suture consisting of an underlying
mattress suture and a more superficial over-and-over suture.
7.1.1. Conventional AVR results
Regardless of surgical approach, elected AVR is the gold standard for the treatment of se‐
vere AS. Several studies have shown acceptable short- and long-term outcomes, as well as
improved quality of life in elderly patients. Although the proportion of elderly patients with
multiple comorbidities is expanding, operative outcomes following AVR were still improv‐
ing in the past decade. Recent series such as Likosky et al [25], report 30-day mortality
among patients who underwent isolated AVR of 3.7% for patients <80, 6.7% in the 80 to 84
age group, and 11.7% in those ages >85 (P<0.001). Among patients undergoing AVR+CABG,
6.2% of patients <80 years died within 30 days, 9.4% among those 80 to 84, and 8.5% of pa‐
tients ≥85 years (P=0.01). Also M. Di Eusanio et al [37] published a multi-centre study in‐
cluding 638 octogenarians who underwent AVR from an Italian regional cardiac surgery
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registry (2003-2009), They report hospital mortality of 4.5%, which favourably compares
with those reported in other series (ranging from 4.3% to 13.7%). Recent surgical series [3,
38] report operative mortality rates for aortic valve replacement as low as 1%, increasing to
9% in higher-risk patients. Long-term survival after valve replacement is 80% at 3 years,
with an age-corrected postoperative survival that is nearly normalized. Significant postoper‐
ative morbidity, such as thromboembolism, haemorrhagic complications from anticoagula‐
tion, prosthetic valve dysfunction, and endocarditis, are rare and occur at a rate of 2% to 3%
per year [38]. These improvements in operative outcome could be related to multiple fac‐
tors, including patient selection and perioperative management.
A number of studies have also examined outcomes of AVR conducted with concomitant
CABG surgery. With few exceptions, concomitant CABG surgery does not increase a pa‐
tient’s operative risk. Considering the mounting evidence for the acceptable perioperative
outcomes after AVR with or without concomitant CABG in the elderly, perhaps the fact that
as many as one-third of patients >80 years of age with severe aortic stenosis are still denied
surgery because of their age is due at least in part to the lack of evidence for long-term out‐
comes. Likosky et al [25] published the outcome of the very elderly undergoing aortic valve
surgery comprising 7584 patients, including 815 over the age of 80. They have demonstrated
that aortic valve replacement with or without concomitant CABG is a safe and effective op‐
tion for elderly patients with severe aortic stenosis. Specifically, more than half of the pa‐
tients undergoing aortic valve procedures were alive 6 years after surgery. Although
concomitant CABG adds a slight mortality risk in the immediate postoperative period, it
does not appreciably affect long-term survival among patients older than 80 years.
Survival has been also improved in elderly patients who underwent AVR. Asimakopoulos
et al [39] reviewed United Kingdom Heart Valve Registry data from 1100 patients >80 years
of age who underwent AVR from January 1986 to December 1995. They reported 30-day
mortality as 6.6% with actuarial survival of 89%, 79.3%, 68.7%, and 45.8% at 1, 3, 5, and 8
years, respectively. Likosky et al [25] report a 6-year survival of 54.7% in patients aged 80 to
84 following AVR and 53.3% in patients aged 80 to 84 following AVR+CABG. Yamane et al
[26] published their single centre study in 2011, reporting Survival at 1, 3, 5, and 10 years in
patients aged 70–79 as 91.6%, 85.1%, 77.2%, and 38.0%, respectively, as compared with
84.1%, 75.7%, 63.0%, and 21.7% in patients aged 80– 92 (P=0.002). More recently M. Di Eusa‐
nio et al [37] report a 1, 3 and 6 year survival of 91.3%, 80.6% and 67.5% respectively in octo‐
genarian patients who underwent isolated AVR.
In several studies, estimates of quality of life, as measured by NYHA functional class im‐
provement, autonomy or satisfaction after receiving surgery have shown excellent function‐
al recovery after AVR in patients >80 years (also see Elderly patient). Wu et al [40] in a
recent study, determining the economic value of the additional life given to patients under‐
going AVR, concluded that AVR is cost-effective for all ages, and still worthwhile in octoge‐
narian and nonagenarian patients.
In conclusion, conventional AVR in selected octogenarians has similar outcomes to those in
“younger” elderly patients, with good mid-term survival and excellent functional recovery
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with a marked improvement in quality of life; in fact, their level of function and quality of
life are the same as a general population of age-matched subjects.
7.2. Minimally Invasive Surgical (MIS) approaches
MIS approaches appear to improve the results observed in conventional surgery. The latter
shows good results with acceptable morbidity and mortality rates in most cases, including
in patients with aortic valve disease, however, in some subgroups of patients these out‐
comes tend to be worse. Minimally invasive surgery aims to minimise the degree of surgical
intrusiveness. Currently there are several surgical approaches. A partial upper sternotomy is
the most frequently used incision for a minimally invasive approach to the aortic valve and
this is usually carried out via a parasternal incision over the second and third intercostal
space, depending on the patient's anatomy as observed in preoperative imaging studies
such as CT. The partial sternotomy is also frequently used, and there are several possible
approaches. The table below summarises the various possible techniques (Table 3).
Partial sternotomy
Para-sternal incision [41,42]
Trans-sternal incision [41]
Upper sternotomy (Byrne et al., 2000) [38]
T mini-sternotomy [44]
V-shaped incision [45]
Inverted L incision [44]
Reversed L incision [46]
J incision [41,47]
Reversed C incision
Inverted T incision [48]
Thoracotomy
Right anterior thoracotomy 2º or 3º inter-costal space [49]
Right anterior thoracotomy 4º or 5º inter-costal space [50]
Video-assisted vision
Port access [51]
Video-direct vision
AESOP 3000 (Computer Motion, Goleta, CA) [52]
Da Vinci System (Intuitive Surgical, Sunnyvale, CA) [53]
Zeus (Computer Motion, Goleta, CA) [41]
Bustamante et al., 2012 [54]
Table 3. Minimally Invasive Approaches.
The “J” incision is the most widely used approach among the partial sternotomy approaches
(Figure 5 & 6).
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Figure 5. A & B: Reversed L incision.
Figure 6. Operative field distribution from surgeon view.
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However there are other approaches that are gaining popularity and some groups are begin‐
ning to use it quite often, so is the case of the right anterior thoracotomy through 2º or 3º
inter-costal space (Figure 7).
Figure 7. Right anterior thoracotomy through 2º or 3º inter-costal space.
Some controversy exists as to the benefits of these approaches. There are currently very few
randomized studies able to answer this question and those that do exist have certain limita‐
tions [55, 56]. However, in the medical literature we do find numerous articles that report
broad series of patients in which the effects can be observed and several aspects of these ap‐
proaches can be compared to conventional approaches.
A series of advantages traditionally exist in the application of MIS for aortic valve replace‐
ment. There is no methodological uniformity across the studies that have been carried out,
which sometimes complicates comparison between studies and makes it difficult to draw
conclusions about the impact of these approaches on patient treatment. This is due to the
fact that the aspects considered by the different studies differ in some cases. For example,
some focus on length of hospitalization and specific complications and others give more
relevance to surgical aspects such time spent with extracorporeal circulation or clamping. In
summary, we can say that there is a group of patients about which there is a certain consen‐
sus as to the benefits of the MIS approaches. This group includes the elderly [50], and pa‐
tients who have previously undergone interventions involving myocardial revascularisation
[43]. In the first case the benefit fundamentally lies in the reduction of surgical aggression in
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cases where patients are more susceptible to developing post-operative complications, lead‐
ing to a much faster functional recovery time compared to patients subjected to convention‐
al interventions. In the second case the benefit lies in the fact that it is not necessary to
dissect the mediastinal structures, thus avoiding the risk of damaging coronary implants,
and the complications that would entail [57, 58].
7.2.1. Advantages and disadvantages of MIS approaches in aortic stenosis
In other patients there are arguments in favour of MIS. Benefits have been observed in cer‐
tain aspects such as:
• Reduction in bleeding in surgery and therefore in the use of hemoderivatives. There are
also discrepancies in this aspect, as while some studies indicate the benefit [55, 59-61],
others, such as Stamou et al [44] do not observe this effect. A possible explanation for this
disparity of results is that in the assessment of reduced post-operative bleeding, no prior
adjustments for risk factors for post-operative bleeding were made. The debate is further
complicated by the fact that Dogan et al [32], observed differences in the reduction of
post-surgical bleeding in a randomised study. In our group we did observe a statistically
significant reduction in blood loss during surgery and in the need for hemoderivatives.
• Reduction in the pain perceived by the patient. Numerous studies indicate this benefit
[55, 62, 63] which is based on a reduction in the distension of costovertebral ligaments and
traction of the brachial plexus. This results in reduced consumption of analgesic pharma‐
ceuticals by the patient.
• Less reduction in tidal lung volume, thus reducing the appearance of respiratory compli‐
cations such as atelectasis by maintaining the integrity of the thorax [56].
• Better aesthetic results. This is one of the clear benefits of the technique, due to the re‐
duced size of the surgical incisions and their relocation to less visible areas.
• There are other benefits, such as the reduction in complications in the surgical wound/ in‐
fections. Grossi et al [64] observe an incidence of infection of 0.9% for minimally invasive
approaches as against 5.7% in cases of patients with the approach by sternotomy, p=0.05.
It has been observed that this difference increases in elderly patients (1.8 and 7.7% respec‐
tively). Other authors observe that in comparison with the classical approach there is a
lesser incidence of infectious complications [65, 66].
A certain consensus exists around the benefits mentioned above. There is also the question
of the impact of MIS on duration of surgery. There is disparity in the results found in the
literature. Along with other research groups, we observed that, once the learning curve has
been overcome, these times tend to equal out and there is no significant difference to be ob‐
served between the different approaches. Studies that support an increase in the time for
cardiopulmonary bypass and aortic clamping are Farhat et al, Detter et al, de Vaumas et al,
and Stamou et al. [44, 46, 48, 67]; contradictory results can be found in Corbi et al., Sharony
et al or the randomised study by Bonachi et al. [45, 50, 55]. Another aspect that is highly val‐
ued in MIS surgery is the impact it has on the duration of hospitalisation and time spent in
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intensive care units. This has been taken into consideration in reducing the cost of the proc‐
ess, in a context of increased life expectancy and rising healthcare costs. In terms of patient
treatment it is relevant in that the reduction of both is accompanied by a lesser incidence of
other complications, basically infections, particularly respiratory infections, surgical wound
infections and urinary tract infections.
7.3. Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter aortic valve implantation (TAVI) was developed as an alternative to AVR in
the very or extremely high-risk patient population. The first implant in man was performed
by Cribier [68] in 2002, using a balloon expandable frame and equine valve. Since the intro‐
duction of minimally invasive and catheter-based therapies, patients want less invasive op‐
tions for all types of medical procedures including general surgical, orthopaedic, spinal, and
urological operations with the goal of decreasing morbidity and mortality and shortening
recovery time. Other issues with traditional aortic and mitral valve surgery include the fact
that patients may not even be offered operation; in multiple series from different centres and
in different countries, up to 40% of patients with severe aortic stenosis are treated medically
[69, 70]. Some of these patients may be deemed to be too sick for surgery because of associat‐
ed medical comorbidities, and some may be considered too old. Finally, some who may ben‐
efit the most from an operation may decline surgery even though they develop irreversible
damage from the valve lesion that could have been treated. These factors have led to the
continuous development of less invasive strategies with lower mortality, lower morbidity,
and less invasiveness [71]. Transcatheter aortic valve replacement seems to offer a new win‐
dow of treatment for those patients with severe aortic valve stenosis that are either extreme‐
ly high-risk or inoperable for conventional aortic valve replacement. Today around 40000
patients have received a transcatheter aortic valve implantation (TAVI) worldwide. Multiple
single- and multi-centre registries, and a single randomized trial, the PARTNER trial (Place‐
ment of AoRTic TraNscathetER Valve Trial), have documented favourable outcomes using a
wide spectrum of endpoints, including survival, symptom status, quality of life, and need
for repeat hospitalization.
7.3.1. Implantation techniques
TAVI is currently carried out using two main approaches (retrograde transfemoral and ante‐
grade transapical), which share the same main principles. Trans-axillary artery or transaortic
are other approaches that are gaining popularity when the transfemoral approach is not fea‐
sible. Specific anatomic issues must be considered in device design. These include the rigid
structure and pattern of the valvular calcification and the aortic annulus, and the need for as
full an apposition as possible to the annulus in an attempt to minimize periprosthetic leaks.
In the case of eccentric, bulky calcifications, this may be difficult. The close proximity to the
coronary ostia, the width and height of the sinuses, the membranous ventricular septum
with the His bundle and the anterior leaflet of the mitral valve are also important anatomical
considerations. In addition, the size and degree of severity of peripheral arterial disease are
all factors that could limit catheter size [15]. It is therefore highly recommended to perform
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an adequate preoperative assessment of the degree of peripheral arterial disease through
imaging studies such as CT (Figure 8).
Figure 8. (A) CT reconstruction of the aorta. (B) CT reconstruction of iliofemoral arteries
Most teams perform the procedure under general anaesthesia, although sedation and an‐
algesia  may  suffice  for  the  transfemoral  approach.  Peri-procedural  transoesophageal
echocardiography (TEE) monitoring is desirable to correctly position the valve as well as
to  detect  complications.  After  crossing  the  aortic  valve,  Balloon  aortic  valvuloplasty  is
performed to pre-dilate the native valve and serve as a rehearsal for TAVI. Simultaneous
rapid  pacing  decreases  cardiac  output,  stabilizing  the  balloon  during  inflation.  Normal
blood pressure must be completely recovered between sequences of rapid pacing. In or‐
der to position the prosthesis  at  the level  of  the aortic  valve annulus different  methods
can be used, such as fluoroscopy to assess the level of valve calcification (Figure 9); aor‐
tography, using different views, performed at the beginning of the procedure and repeat‐
ed with the undeployed prosthesis  in place,  to  determine the position of  the valve and
the  plane  of  alignment  of  the  aortic  cusps;  and  echocardiography.  TEE  is  particularly
helpful in cases with moderate calcification.
Three dimensional real-time TEE seems to provide extra information to the teams that use it.
When positioning is considered correct, the prosthesis is released. Rapid pacing is used at
this stage for balloon-expandable devices but not for self-expanding ones. Immediately after
TAVI, aortography and, whenever available, TEE or, in the absence of TEE, Transthoracic
echocardiogram(TTE) are performed to assess the location and degree of aortic regurgitation
and the patency of the coronary arteries, and to rule out complications such as haemoperi‐
cardium, and aortic dissection. The hemodynamic results are assessed using pressure re‐
cordings and/or echocardiography. After the procedure, the patients should stay in
intensive care for at least 24 hours and be closely monitored for several days, particularly as
regards hemodynamics, vascular access, rhythm disturbances (especially late atrioventricu‐
lar block), and renal function.
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Figure 9. First row (A). Edwards Sapiens transfemoral implantation. Second row (B). Transfemoral Corevalve implanta‐
tion. Third row (C). Edwards Sapiens transapical implantation.
The specific issues related to the different approaches include the following: In the transfe‐
moral approach, close attention should be paid to the vascular access. The common femoral
artery can be either prepared surgically or approached percutaneously. Echo-guided femo‐
ral access could be useful. Manipulation of the introductory sheaths should be careful and
fluoroscopically guided. Depending on the size of the device, closure of the vascular access
can be effected surgically or using a percutaneous closure device. Femoral access and cardi‐
opulmonary bypass should be on standby for patients for whom surgical conversion is an
option in case of complications.
The transapical approach requires an antero-lateral mini-thoracotomy (Figure 10), pericar‐
diotomy, identification of the apex, and then puncture of the left ventricle using a needle
through purse-string sutures. Subsequently, an introductory sheath is positioned in the LV,
and the prosthesis is implanted using the antegrade route.
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Figure 10. Anterior minitoracotomy for transapical approach of a TAVI procedure.
7.3.2. TAVR results
The PARTNER trial has been followed with great interest. The PARTNER trial was basically
2 parallel trials: 1) PARTNER Cohort A, which randomized high-risk surgical patients to ei‐
ther traditional aortic valve replacement or to TAVI by either a transfemoral or transapical
approach; and 2) PARTNER Cohort B in which patients who were inoperable were random‐
ized to either a TAVR by a transfemoral approach or to conventional medical therapy,
which typically consisted of balloon aortic valvuloplasty.
Screening required evaluation by 2 experienced cardiac surgeons to agree on the surgical
risk using the STS Predicted Risk of Mortality score and was rigorous, with approximately
one-quarter to one-third of screened patients subsequently enrolled. The primary endpoint
was death from any cause at 1 year. The results of PARTNER Cohort B included 358 patients
deemed unsuitable for conventional aortic valve replacement because of predicted probabil‐
ity of≥ 50% mortality or the risk of a serious irreversible complication within 30 days. At 1
year, all-cause mortality with TAVR was 30.7% versus 50.7% with medical therapy (hazard
ratio: 0.55, 95% confidence interval: 0.40 to 0.74). Despite the marked improvement in sur‐
vival and event-free survival, there were some significant safety hazards, particularly a
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higher incidence of major strokes (5.0% versus 1.1%) as well as increased major vascular
complications (16.2% versus 1.1%) with TAVR, both of which may adversely impact early
and longer-term outcome. Longer-term outcomes will be required. These results were re‐
ceived enthusiastically; however, they have important limitations. Firstly, they can be ap‐
plied only in patients similar to those in the study (i.e., those patients deemed to be
inoperable). Secondly, they are the result of treatment by very experienced operators work‐
ing as a heart team in a hybrid operating room or similar facility with a specific device and
do not necessarily apply to other devices.
The  results  of  the  PARTNER Cohort  A trial  also  have  important  implications.  The  pri‐
mary endpoint of the trial  was met,  with TAVR found not to be inferior to aortic valve
replacement  for  all-cause  mortality  at  1  year  (TAVR  versus  aortic  valve  replacement,
24.2% versus 26.8%, respectively, p₌0.001 for non-inferiority). Death at 30 days was lower
than expected in both arms of the trial:  TAVR mortality (3.4%) was the lowest reported
in  any  series,  despite  an  early  generation  device  and  limited  previous  operator  experi‐
ence.  Aortic  valve  replacement  mortality  (6.5%)  was  lower  than  the  expected  operative
mortality (11.8%). Furthermore, both TAVR and aortic valve replacement were associated
with important but different peri-procedural hazards: major strokes at 30 days (3.8% ver‐
sus  2.1%,  p=0.20)  and  1  year  (5.1% versus  2.4%,  p=0.07),  and  major  vascular  complica‐
tions were more frequent with TAVR (11.0% versus 3.2%, p<0.001). Major bleeding (9.3%
versus 19.5%, p<0.001) and new onset atrial fibrillation (8.6% versus 16.0%, p<0.001) were
more frequent with aortic valve replacement.
Rates of stroke were similar whether the access was transfemoral or transapical. Biopros‐
thetic-valve gradients and orifice areas were slightly better after transcatheter replacement
than after surgical replacement, probably because of the less bulky support frame with
transcatheter replacement [34]. However, transcatheter replacement resulted in much more
frequent paravalvular aortic regurgitation. Although this condition was stable at 1 year, re‐
peat intervention was required in some cases. A reduction in the incidence and severity of
paravalvular AR represents an obvious target for technical improvements in the design of
transcatheter valves and of implantation techniques [24]. Clinical benefits of transcatheter
replacement included significantly shorter stays in the intensive care unit and in hospital. In
addition, the NYHA functional class and 6-minute walk distance were strikingly improved
at 1 year [34]. Transcatheter aortic valve implantation by means of either the transfemoral or
the transapical approach is a reasonable and promising treatment option for patients who
are at high risk or had been refused for conventional AVR. Recommendations made to indi‐
vidual patients must balance the appeal of avoiding the known risks of open-heart surgery
against the less invasive transcatheter approach, which has different and less well under‐
stood risks, particularly with respect to stroke and paravalvular aortic regurgitation.
8. New prostheses in mini-invasive approaches
These prostheses were designed by industry with a view to facilitating the implantation of
the prosthesis through conventional surgery; that is to say, using a cardio-pulmonary by‐
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pass and aortic clamping. The gold standard for the use of these prostheses is in association
with MIS approaches, providing a reduction in surgical aggression in addition to the reduc‐
tion in ECC and aortic clamping time, the consequences of which we have already exam‐
ined. These designs have the common feature of being expandable, anchoring themselves to
the aortic ring in a similar way to the devices used in TAVI.
To date there are three commercially available models: 3f Enable ® (Medtronic Inc, Minne‐
apolis, MN), Perceval S (Sorin Group Cardio Srl, Sallugia, Italy) and Intuity (Edwards Life‐
sciences, Irvine, California). These differ from each other in a few characteristics.
3f Enable ® aortic bioprosthesis (Figure 11): This prosthesis is especially indicated in pa‐
tients with small aortic annulus where the possibility of having a severe mismatch is high
with the use of conventional prosthesis. Several studies report an acceptable hemodynamic
behavior with this type of prosthesis. Furthermore, there is no need to match the measure
between the annulus and the sinotubular junction, because the prosthesis is anchored only
to the annulus. Of the three prostheses this is the oldest and different models have been de‐
veloped since its initial commercialisation with a view to improving hemodynamics, dura‐
bility and facilitating surgeons in its implantation [72-74]
Figure 11. Enable ® (Medtronic Inc, Minneapolis, MN)
Perceval S (Sorin Biomedica Cardio Srl, Sallugia, Italy) (Figure 12): Prosthesis aimed at pa‐
tients with a high surgical risk in which a reduction in surgery time may have a significant
impact, for patients where it is necessary to carry out mixed procedures, and patients under‐
going re-intervention, and patients with a small aortic ring, because of the hemodynamic
characteristics of the prosthesis [75, 76]
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Figure 12. Perceval S (Sorin Biomedica Cardio Srl, Sallugia, Italy)
Intuity (Edwards Lifesciences, Irvine, California) (Figure 13): Of these three prostheses this
is the most recently commercialised and results as to its hemodynamic profile and durability
in clinical practice are not available. Arguments in its favour, as put forward by the compa‐
ny, are the conjunction between the Edwards Perimount bioprosthesis, the clinical and he‐
modynamic results of which are widely known, and the experience in the development of
new prostheses such as the Sapien transcatheter. The mode of implantation for this prosthe‐
sis allows the aortic clamping and extracorporeal circulation times to be reduced. For a
number of reasons, one of the most important being ischemic reperfusion, these two varia‐
bles are known to be directly related to the surgical morbidity and mortality of procedures,
which is why this model may be attractive, in addition to the comfort of implantation, as it
does not require stitches in the aortic ring.
Figure 13. Intuity (Edwards Lifesciences, Irvine, California)
The disadvantage of these prostheses is their cost, as they ultimately increase resource con‐
sumption. Results for hemodynamics and durability are becoming better understood as pre‐
liminary studies are published. From the beginning we find data in the literature relating to
safety and effectiveness in the implantation of aortic valve replacements. Some of the com‐
plications associated with their use, such as perivalvular leaks are understood to be inti‐
mately related to the decalcification of the ring; in some cases, it has been possible to correct
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other complications, such as bad positioning, with new designs being applied to the already
existing prosthetics [77]
9. Conclusions
Medical science is progressing faster than ever and the field of cardiovascular disease is one
of its greatest exponents. Patient care and treatment must adapt to changing patient charac‐
teristics as well as to new technologies and treatment options. In the case of aortic valve dis‐
ease, whose prevalence is booming in the western world, we must be capable of a
comprehensive approach to ensure optimal results and efficient use of resources. Currently,
age, per se, is not a contraindication for the treatment of aortic valve disease; hence a thor‐
ough assessment should be undertaken to design the best therapeutic approach for high-risk
patients. Understanding of treatment options of this disease has increased. New devices
have been developed and advances have been made in perioperative management of car‐
diac surgical patients. Nevertheless, there is still room for improvement in this interesting
field of cardiac surgery.
Author details
Omer Leal1, Juan Bustamante1*, Sergio Cánovas2 and Ángel G. Pinto3
*Address all correspondence to: jbustamantemunguira@gmail.com
1 Department of Cardiovascular Surgery, Hospital Universitario La Princesa, Madrid, Spain
2 Department of Cardiac Surgery, Hospital General Universitario de Valencia, Valencia,
Spain
3 Department of Cardiac Surgery, Hospital Universitario Gragorio Marañon, Madrid, Spain
References
[1] Schmitto J.D., Mohr F.W., Cohn L.H. Minimally invasive aortic valve replacement:
how does this perform in high-risk patients? Curr Opin Cardiol. 2011; 26(2):118-122.
[2] Chambers J.B. Aortic stenosis. Eur J Echocardiogr. 2009; 10(1):i11-9.
[3] Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, dis‐
ease progression, and treatment strategies. Circulation. 2005 Jun 21;111(24):
3316-3326.
Calcific Aortic Valve Disease476
[4] Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve
sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med.
1999 15;341(3):142-147.
[5] Kurtz CE, Otto CM. Aortic stenosis: clinical aspects of diagnosis and management,
with 10 illustrative case reports from a 25-year experience. Medicine (Baltimore).
2010;89(6):349-379.
[6] Steadman CD, Ray S, Ng LL, McCann GP. Natriuretic peptides in common valvular
heart disease. J Am Coll Cardiol 2010;55:2034–2048.
[7] Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Na‐
triuretic peptides predict symptom-free survival and postoperative outcome in se‐
vere aortic stenosis. Circulation 2004; 109:2302–2308.
[8] Monin JL, Lancellotti P, Monchi M, Lim P, Weiss E, Pie´rard L, et al., Risk score for
predicting outcome in patients with asymptomatic aortic stenosis. Circulation
2009;120:69–75.
[9] Lancellotti P, Moonen M, Magne J, O’Connor K, Cosyns B, Attena E, et al., Prognostic
effect of long-axis left ventricular dysfunction and B-type natriuretic peptide levels in
asymptomatic aortic stenosis. Am J Cardiol 2010; 105:383–388.
[10] Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al.
2008 focused update incorporated into the ACC/AHA 2006 guidelines for the man‐
agement of patients with valvular heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to revise the 1998 guidelines for the management of patients with valvu‐
lar heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Soci‐
ety for Cardiovascular Angiography and Interventions, and Society of Thoracic
Surgeons. J Am Coll Cardiol. 2008 23;52(13):e1-142.
[11] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H,
et al. Guidelines on the management of valvular heart disease (version 2012): The
Joint Task Force on the Management of Valvular Heart Disease of the European Soci‐
ety of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Eur J Cardiothorac Surg. 2012 27. doi:10.1093/eurheartj/ehs109.
[12] Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guide‐
lines on the management of valvular heart disease: The Task Force on the Manage‐
ment of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J.
2007;28(2):230-268.
[13] Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al.
American Society of Echocardiography; European Association of Echocardiography.
Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for
practice. J Am Soc Echocardiogr. 2009;22(1):1-23.
[14] Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38(1 Suppl):61-67.
New Therapeutic Approaches to Conventional Surgery for Aortic Stenosis in High-Risk Patients
http://dx.doi.org/10.5772/54333
477
[15] Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012
ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve re‐
placement: developed in collaboration with the American Heart Association, Ameri‐
can Society of Echocardiography, European Association for Cardio Thoracic Surgery,
Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anes‐
thesiologists, Society of Cardiovascular Computed Tomography, and Society for Car‐
diovascular Magnetic Resonance. Ann Thorac Surg. 2012;93(4):1340-1395.
[16] Grant SW, Hickey GL, Dimarakis I, Trivedi U, Bryan A, Treasure T, et al. How does
EuroSCORE II perform in UK cardiac surgery; an analysis of 23 740 patients from the
Society for Cardiothoracic Surgery in Great Britain and Ireland National Database.
Heart. 2012 Aug 21. doi:10.1136/heartjnl-2012-302483.
[17] Frilling B, von Renteln Kruse W, Riess FC. Evaluation of operative risk in elderly pa‐
tients undergoing aortic valve replacement: the predictive value of operative risk
scores. Cardiology. 2010;116(3):213-218.
[18] Thielmann M, Wendt D, Eggebrecht H, Kahlert P, Massoudy P, Kamler M, et al.
Transcatheter aortic valve implantation in patients with very high risk for conven‐
tional aortic valve replacement. Ann Thorac Surg. 2009;88(5):1468-1474.
[19] Rosenhek R, Iung B, Tornos P, Antunes MJ, Prendergast BD, Otto CM, et al. ESC
Working Group on Valvular Heart Disease Position Paper: assessing the risk of inter‐
ventions in patients with valvular heart disease. Eur Heart J. 2012;33(7):822-828.
[20] Bustamante J, Gómez-Martínez ML, Bustamante E, Tamayo E. Occult chronic kidney
disease in the ederly with coronary heart disease. Med Clin (Barc). 2009;133(13):524.
[21] Herreros JM. Cardiac surgery in elderly patients. Rev Esp Cardiol. 2002;55(11):
1114-1116.
[22] Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities
in the elderly: an echocardiographic study of a random population sample. J Am Coll
Cardiol. 1993;21(5):1220-1225.
[23] Rodríguez R, Torrents A, García P, Ribera A, Permanyer G, Moradi M, et al. Cardiac
surgery in elderly patients. Rev Esp Cardiol. 2002;55(11):1159-1168.
[24] Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, et
al. Long-term outcomes after transcatheter aortic valve implantation in high-risk pa‐
tients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter
Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011;58(20):2130-2138.
[25] Likosky DS, Sorensen MJ, Dacey LJ, Baribeau YR, Leavitt BJ, DiScipio AW, et al.
Long-term survival of the very elderly undergoing aortic valve surgery. Circulation.
2009;120(11 Suppl):S127-133.
[26] Yamane K, Hirose H, Youdelman BA, Bogar LJ, Diehl JT. Conventional aortic valve
replacement for elderly patients in the current era. Circ J. 2011;75(11):2692-2698.
Calcific Aortic Valve Disease478
[27] Brown JM, O'Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic
valve replacement in North America comprising 108,687 patients in 10 years:
changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons Na‐
tional Database. J Thorac Cardiovasc Surg. 2009;137(1):82-90.
[28] Huber CH, Goeber V, Berdat P, Carrel T, Eckstein F. Benefits of cardiac surgery in
octogenarians a postoperative quality of life assessment. Eur J Cardiothorac Surg.
2007;31(6):1099-1105.
[29] Kolh P, Lahaye L, Gerard P, Limet R. Aortic valve replacement in the octogenarians:
perioperative outcome and clinical follow-up. Eur J Cardiothorac Surg. 1999;16(1):
68-73.
[30] Maillet JM, Somme D, Hennel E, Lessana A, Saint-Jean O, Brodaty D. Frailty after
aortic valve replacement (AVR) in octogenarians. Arch Gerontol Geriatr. 2009;48(3):
391-396.
[31] Sundt TM, Bailey MS, Moon MR, Mendeloff EN, Huddleston CB, Pasque MK, et al.
Quality of life after aortic valve replacement at the age of >80 years. Circulation.
2000;102(19 Suppl 3):III70-74.
[32] Dogan S, Dzemali O, Wimmer-Greinecker G, Derra P, Doss M, Khan MF, et al. Mini‐
mally invasive versus conventional aortic valve replacement: a prospective random‐
ized trial. J Heart Valve Dis. 2003;12(1):76-80.
[33] Martens S, Sadowski J, Eckstein FS, Bartus K, Kapelak B, Sievers HH, et al. Clinical
experience with the ATS 3f Enable® Sutureless Bioprosthesis. Eur J Cardiothorac
Surg. 2011;40(3):749-755.
[34] Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcathet‐
er versus surgical aortic-valve replacement in high-risk patients. N Engl J Med.
2011;364(23):2187-2198.
[35] Harken, D.E., Soroff, H.S., Taylor, W.H. Aortic valve replacement, in Merendino KA
(ed): Prosthetic Valves for Cardiac Surgery. Springfield, IL, Thomas; 1961, p 508-526
[36] Starr A, Edwards ML. Mitral replacement: clinical experience with a ball-valve pros‐
thesis. Ann Surg. 1961; 154:726-740.
[37] Di Eusanio M, Fortuna D, Cristell D, Pugliese P, Nicolini F, Pacini D, et al. Contem‐
porary outcomes of conventional aortic valve replacement in 638 octogenarians: in‐
sights from an Italian Regional Cardiac Surgery Registry (RERIC). Eur J Cardiothorac
Surg. 2012;41(6):1247-1252.
[38] Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Car‐
diol. 2010;55(22):2413-2426.
[39] Asimakopoulos G, Edwards MB, Taylor KM. Aortic valve replacement in patients 80
years of age and older: survival and cause of death based on 1100 cases: collective
results from the UK Heart Valve Registry. Circulation. 1997;96(10):3403-3408.
New Therapeutic Approaches to Conventional Surgery for Aortic Stenosis in High-Risk Patients
http://dx.doi.org/10.5772/54333
479
[40] Wu Y, Jin R, Gao G, Grunkemeier GL, Starr A. Cost-effectiveness of aortic valve re‐
placement in the elderly: an introductory study. J Thorac Cardiovasc Surg.
2007;133(3):608-613.
[41] Cohn LH, Adams DH, Couper GS, Bichell DP, Rosborough DM, Sears SP, Aranki SF.
Minimally invasive cardiac valve surgery improves patient satisfaction while reduc‐
ing costs of cardiac valve replacement and repair. Ann Surg. 1997;226(4):421-426.
[42] Navia JL, Cosgrove DM 3rd. Minimally invasive mitral valve operations. Ann Thorac
Surg. 1996;62(5):1542-1544
[43] Byrne JG, Karavas AN, Adams DH, Aklog L, Aranki SF, Couper GS, Rizzo RJ, Cohn
LH, et al. Partial upper re-sternotomy for aortic valve replacement or re-replacement
after previous cardiac surgery. Eur J Cardiothorac Surg. 2000;18(3):282-286.
[44] Stamou SC, Kapetanakis EI, Lowery R, Jablonski KA, Frankel TL, Corso PJ. Allogene‐
ic blood transfusion requirements after minimally invasive versus conventional aort‐
ic valve replacement: a risk-adjusted analysis. Ann Thorac Surg. 2003;76(4):
1101-1106.
[45] Corbi P, Rahmati M, Donal E, Lanquetot H, Jayle C, Menu P, et al. Prospective com‐
parison of minimally invasive and standard techniques for aortic valve replacement:
initial experience in the first hundred patients. J Card Surg. 2003;18(2):133-139.
[46] Detter C, Deuse T, Boehm DH, Reichenspurner H, Reichart B. Midterm results and
quality of life after minimally invasive vs. conventional aortic valve replacement.
Thorac Cardiovasc Surg. 2002;50(6):337-341.
[47] Doll N, Borger MA, Hain J, Bucerius J, Walther T, Gummert JF, et al. Minimal access
aortic valve replacement: effects on morbidity and resource utilization. Ann Thorac
Surg. 2002;74(4):S1318-1322.
[48] Farhat F, Lu Z, Lefevre M, Montagna P, Mikaeloff P, Jegaden O. Prospective compar‐
ison between total sternotomy and ministernotomy for aortic valve replacement. J
Card Surg. 2003;18(5):396-401.
[49] Burfeind WR, Glower DD, Davis RD, Landolfo KP, Lowe JE, Wolfe WG. Mitral sur‐
gery after prior cardiac operation: port-access versus sternotomy or thoracotomy.
Ann Thorac Surg. 2002;74(4):S1323-1325.
[50] Sharony R, Grossi EA, Saunders PC, Schwartz CF, Ribakove GH, Culliford AT, et al.
Minimally invasive aortic valve surgery in the elderly: a case control study. Circula‐
tion. 2003;108 Suppl 1:II43-47.
[51] Galloway AC, Shemin RJ, Glower DD, Boyer JH Jr, Groh MA, Kuntz RE, et al. First
report of the Port Access International Registry. Ann Thorac Surg. 1999;67(1):51-56.
[52] Falk V, Walther T, Autschbach R, Diegeler A, Battellini R, Mohr FW. Robot-assisted
minimally invasive solo mitral valve operation. J Thorac Cardiovasc Surg.
1998;115(2):470-471.
Calcific Aortic Valve Disease480
[53] Carpentier A, Loulmet D, Aupècle B, Kieffer JP, Tournay D, Guibourt P, et al. Com‐
puter assisted open heart surgery. First case operated on with success. C R Acad Sci
III. 1998;321(5):437-442.
[54] Bustamante J, Cánovas S, Fernández AL, Minimally Invasive Aortic Valve Surgery -
New Solutions to Old Problems In Hirota M (Ed) Aortic Stenosis - Etiology, Patho‐
physiology and Treatment. Rijeka: InTech; 2012. p 91-114.
[55] Bonacchi M, Prifti E, Giunti G, Frati G, Sani G. Does ministernotomy improve post‐
operative outcome in aortic valve operation? A prospective randomized study. Ann
Thorac Surg. 2002;73(2):460-465.
[56] Moustafa MA, Abdelsamad AA, Zakaria G, Omarah MM. Minimal vs median ster‐
notomy for aortic valve replacement. Asian Cardiovasc Thorac Ann. 2007;15(6):
472-475.
[57] Yap CH, Sposato L, Akowuah E, Theodore S, Dinh DT, Shardey GC, et al. Contem‐
porary results show repeat coronary artery bypass grafting remains a risk factor for
operative mortality. Ann Thorac Surg. 2009;87(5):1386-1391.
[58] Yau TM, Borger MA, Weisel RD, Ivanov J. The changing pattern of reoperative coro‐
nary surgery: trends in 1230 consecutive reoperations. J Thorac Cardiovasc Surg.
2000;120(1):156-163.
[59] Cosgrove DM 3rd, Sabik JF, Navia JL. Minimally invasive valve operations. Ann
Thorac Surg. 1998;65(6):1535-1538.
[60] Tam RK, Almeida AA. Minimally invasive aortic valve replacement via partial ster‐
notomy. Ann Thorac Surg. 1998;65(1):275-276.
[61] Mächler HE, Bergmann P, Anelli-Monti M, Dacar D, Rehak P, Knez I, et al. Minimal‐
ly invasive versus conventional aortic valve operations: a prospective study in 120
patients. Ann Thorac Surg. 1999;67(4):1001-1005.
[62] Candaele S, Herijgers P, Demeyere R, Flameng W, Evers G. Chest pain after partial
upper versus complete sternotomy for aortic valve surgery. Acta Cardiol. 2003;58(1):
17-21.
[63] Liu J, Sidiropoulos A, Konertz W. Minimally invasive aortic valve replacement
(AVR) compared to standard AVR. Eur J Cardiothorac Surg. 1999;16 Suppl 2:S80-83.
[64] Grossi EA, Galloway AC, Ribakove GH, Zakow PK, Derivaux CC, Baumann FG,et al.
Impact of minimally invasive valvular heart surgery: a case control study. Ann Thor‐
ac Surg. 2001;71(3):807-810.
[65] Lee JW, Lee SK, Choo SJ, Song H, Song MG. Routine minimally invasive aortic valve
procedures. Cardiovasc Surg. 2000;8(6):484-490.
[66] Tabata M, Umakanthan R, Cohn LH, Bolman RM 3rd, Shekar PS, Chen FY, et al. Ear‐
ly and late outcomes of 1000 minimally invasive aortic valve operations. Eur J Cardi‐
othorac Surg. 2008;33(4):537-541.
New Therapeutic Approaches to Conventional Surgery for Aortic Stenosis in High-Risk Patients
http://dx.doi.org/10.5772/54333
481
[67] de Vaumas C, Philip I, Daccache G, Depoix JP, Lecharny JB, Enguerand D, et al.
Comparison of minithoracotomy and conventional sternotomy approaches for valve
surgery. J Cardiothorac Vasc Anesth. 2003;17(3):325-328.
[68] Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous
transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:
first human case description. Circulation. 2002;106(24):3006-3008.
[69] Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe
symptomatic aortic stenosis. J Heart Valve Dis. 2006;15(3):312-321.
[70] Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Out‐
come of 622 adults with asymptomatic, hemodynamically significant aortic stenosis
during prolonged follow-up. Circulation. 2005;111(24):3290-3295.
[71] Holmes DR Jr, Mack MJ. Transcatheter valve therapy a professional society overview
from the American college of cardiology foundation and the society of thoracic sur‐
geons. J Am Coll Cardiol. 2011;58(4):445-455.
[72] Cox JL, Ad N, Myers K, Gharib M, Quijano RC. Tubular heart valves: a new tissue
prosthesis design- preclinical evaluation of the 3F aortic bioprosthesis. J Thorac Car‐
diovasc Surg. 2005;130(2):520-527.
[73] Pillai R, Ratnatunga C, Soon JL, Kattach H, Khalil A, Jin XY. 3f prosthesis aortic cusp
replacement: implantation technique and early results. Asian Cardiovasc Thorac
Ann. 2010;18(1):13-16.
[74] Wendt D, Thielmann M, Buck T, Jánosi RA, Bossert T, Pizanis N, et al. First clinical
experience and 1-year follow-up with the sutureless 3F-Enable aortic valve prosthe‐
sis. Eur J Cardiothorac Surg. 2008;33(4):542-547.
[75] Flameng W, Herregods MC, Hermans H, Van der Mieren G, Vercalsteren M, Poort‐
mans G, et al. Effect of sutureless implantation of the Perceval S aortic valve biopros‐
thesis on intraoperative and early postoperative outcomes. J Thorac Cardiovasc Surg.
2011;142(6):1453-1457.
[76] Shrestha M, Folliguet T, Meuris B, Dibie A, Bara C, Herregods MC, et al. Sutureless
Perceval S aortic valve replacement: a multicenter, prospective pilot trial. J Heart
Valve Dis. 2009;18(6):698-702.
[77] Aymard T, Kadner A, Walpoth N, Göber V, Englberger L, Stalder M, et al. Clinical
experience with the second-generation 3f Enable sutureless aortic valve prosthesis. J
Thorac Cardiovasc Surg. 2010;140(2):313-316.
Calcific Aortic Valve Disease482
